β-catenin

Beta catenin

β-catenin is a dual function protein, regulating the coordination of cell–cell adhesion and gene transcription. In humans, the CTNNB1 protein is encoded by the CTNNB1 gene. β-catenin is a subunit of the cadherin protein complex and acts as an intracellular signal transducer in the Wnt signaling pathway. It is a member of the catenin protein family and homologous to γ-catenin. Mutations and overexpression of β-catenin are associated with many cancers, including hepatocellular carcinoma, colorectal carcinoma, lung cancer,malignant breast tumors, ovarian and endometrial cancer. β-catenin is regulated and destroyed by the beta-catenin destruction complex, and in particular by the adenomatous polyposis coli (APC) protein, encoded by the tumour-suppressing APC gene. Therefore genetic mutation of the APC gene is also strongly linked to cancers, and in particular colorectal cancer resulting from familial adenomatous polyposis (FAP).

β-catenin Inhibitors, Agonists, Antagonists & Activators

(E)-Ferulic acid

((E)-Coniferic acid) Cat. No.: HY-N0060B

(E)-Ferulic acid is a isomer of Ferulic acid which is an aromatic compound, abundant in plant cell walls.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

(E)-Ferulic acid-d3

((E)-Coniferic acid-d3) Cat. No.: HY-N0060BS

(E)-Ferulic acid-d3 ((E)-Coniferic acid-d3) is the deuterium labeled (E)-Ferulic acid. (E)-Ferulic acid is a isomer of Ferulic acid which is an aromatic compound, abundant in plant cell walls.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Astragaloside I

(Astrasieversianin IV; Cyclosieversioside B) Cat. No.: HY-N0432

Astragaloside I, one of the main active ingredients in Astragalus membranaceus, has osteogenic properties. Astragaloside I stimulates osteoblast differentiation through the **Wnt/β-catenin** signaling pathway.
.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cardiogenol C

Cat. No.: HY-12319

Cardiogenol C is a potent cell-permeable pyrimidine inducer which prompts the **differentiation of ESCs into cardiomyocytes** (EC_{50}=100 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cardiogenol C hydrochloride

Cat. No.: HY-12319A

Cardiogenol C hydrochloride is a potent cell-permeable pyrimidine inducer which prompts the **differentiation of ESCs into cardiomyocytes** (EC_{50}=100 nM).



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CCT031374 hydrobromide

Cat. No.: HY-108441

CCT 031374 hydrobromid is a potent inhibitor of **β-catenin/transcription factor (TCF)** complex signaling. CCT031374 inhibits TCF-dependent transcription of genes of Wnt signaling pathway. CCT 031374 has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CWP232228

Cat. No.: HY-18959

CWP232228, a highly potent selective **Wnt/β-catenin** signaling inhibitor, antagonizes binding of β-catenin to T-cell factor (TCF) in the nucleus.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

DK419

Cat. No.: HY-112799

DK419 is a potent and orally active **Wnt/β-catenin** signaling inhibitor, with an IC_{50} of 0.19 μM. DK419 reduces protein lelvels of Axin2, β-catenin, c-Myc, Cyclin D1 and Survivin and induces production of pAMPK.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

FH535

Cat. No.: HY-15721

FH535 is an inhibitor of **Wnt/β-catenin** and **PPAR**, with anti-tumor activities.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

FzM1

Cat. No.: HY-116553

FzM1 is a negative allosteric modulator (NAM) of **Frizzled receptor FZD4**. FzM1 reduces WNT5A-dependent WNT responsive element (WRE) activity (log EC_{50inh}=−6.2).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FzM1.8

Cat. No.: HY-117163

FzM1.8 derives from FzM1, is an allosteric agonist of **FZD4** with **pEC_{50}** of 6.4. FzM1.8 binds to FZD4 and activates the **WNT/β-catenin** pathway, by promoting TCF/LEF transcriptional activity in the absence of any WNT ligand.



Purity: 98.20%
Clinical Data:
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg

ICG-001

Cat. No.: HY-14428

ICG-001 is an inhibitor of **β-catenin/TCF** mediated transcription. ICG-001 works by specifically binding to cyclic AMP response element-binding protein with an **IC_{50}** of 3 μM. ICG-001 selectively blocks the β-catenin/CBP interaction without interfering with the β-catenin/p300 interaction.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

iCRT-5

Cat. No.: HY-119383

iCRT-5 is a **β-catenin-regulated transcription (CRT)** inhibitor. iCRT-5 can block **Wnt/β-catenin** reporter activity and down regulate β-catenin expression. iCRT-5 can be used for the research of multiple myeloma.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KY1220

Cat. No.: HY-102028

KY1220 is a compound that destabilizes both β-catenin and Ras, via targeting the **Wnt/β-catenin** pathway; with an **IC_{50}** of 2.1 μM in HEK293 reporter cells.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KY19382

(A3051)

Cat. No.: HY-131447

KY19382 is a potent and orally active dual inhibitor of **CXXC5-DVL** and **GSK3β**, with **IC_{50}**s of 19 and 10 nM, respectively. KY19382 activates Wnt/β-catenin signaling through inhibitory effects on both CXXC5-DVL interaction and GSK3β activity.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KYA1797K

Cat. No.: HY-101090

KYA1797K is a potent and selective **Wnt/β-catenin** inhibitor with an **IC_{50}** of 0.75 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

L-Quebrachitol

Cat. No.: HY-N2375

L-Quebrachitol is a natural product isolated from many plants, promotes osteoblastogenesis by upregulation of **BMP-2**, runt-related transcription factor-2 (**Runx2**), **MAPK** (ERK, JNK, p38α), and **Wnt/β-catenin** signaling pathway.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Laduviglusib

(CHIR-99021; CT99021)

Cat. No.: HY-10182

Laduviglusib (CHIR-99021) is a potent and selective **GSK-3α/β** inhibitor with **IC_{50}**s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for **GSK-3** over CDC2, ERK2 and other protein kinases.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Laduviglusib monohydrochloride

(CHIR-99021 monohydrochloride; CT99021 monohydrochloride)

Cat. No.: HY-10182A

Laduviglusib (CHIR-99021) monohydrochloride is a potent and selective **GSK-3α/β** inhibitor with **IC_{50}**s of 10 nM and 6.7 nM. Laduviglusib monohydrochloride shows >500-fold selectivity for **GSK-3** over CDC2, ERK2 and other protein kinases.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Laduviglusib trihydrochloride

(CHIR-99021 trihydrochloride; CT99021 trihydrochloride)

Cat. No.: HY-10182B

Laduviglusib (CHIR-99021) trihydrochloride is a potent and selective **GSK-3α/β** inhibitor with **IC_{50}**s of 10 nM and 6.7 nM. Laduviglusib trihydrochloride shows >500-fold selectivity for **GSK-3** over CDC2, ERK2 and other protein kinases.



Purity: 98.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

LF3

Cat. No.: HY-101486

LF3 is an antagonist of the **β-Catenin/TCF4** interaction with antitumor activity; has an IC_{50} of 1.65 μM.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MSAB

Cat. No.: HY-120697

MSAB is a potent and selective inhibitor of **Wnt/β-catenin** signaling. MSAB binds to β-catenin promoting its degradation, and specifically downregulates Wnt/β-catenin target genes. MSAB exhibits potent anti-tumor effects selectively on Wnt-dependent cancer cells.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide

Cat. No.: HY-N7702

N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide is a macamide isolated from Maca (Lepidium meyenii Walp.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

N-Desmethylnefopam

Cat. No.: HY-133115

N-Desmethylnefopam is the main metabolite of Nefopam. N-Desmethylnefopam is a centrally-acting but non-opioid analgesic agent, for the relief of moderate to severe pain. Nefopam targets **β-catenin** protein level in mesenchymal cells in-vitro and in-vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Desmethylnefopam D5 hydrochloride

Cat. No.: HY-133115AS

N-Desmethylnefopam D5 hydrochloride is a deuterium labeled N-Desmethylnefopam hydrochloride. N-Desmethylnefopam hydrochloride is the main metabolite of Nefopam.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nefopam D3 hydrochloride

Cat. No.: HY-B1057S

Nefopam D3 hydrochloride is the deuterium labeled Nefopam hydrochloride. Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nefopam hydrochloride

(Fenazoxine hydrochloride)

Cat. No.: HY-B1057

Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo.



Purity: 99.78%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Nefopam-d3

(Fenazoxine-d3)

Cat. No.: HY-B1057S2

Nefopam D3 (Fenazoxine D3) is a deuterium labeled Nefopam (Fenazoxine). Nefopam is a centrally-acting but non-opioid analgesic drug, and Nefopam targets β-catenin protein level in mesenchymal cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nefopam-d4 hydrochloride

(Fenazoxine-d4 hydrochloride)

Cat. No.: HY-B1057S1

Nefopam-d4 (hydrochloride) is deuterium labeled Nefopam (hydrochloride). Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NLS-StAx-h

Cat. No.: HY-P2272

NLS-StAx-h is a selective, stapled peptide inhibitor of **Wnt** signaling with an IC_{50} of 1.4 μM. NLS-StAx-h efficiently inhibits β-catenin-transcription factor interactions. NLS-StAx-h inhibits proliferation and migration of colorectal cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 μg

NRX-103094

Cat. No.: HY-141449

NRX-103094 is a potent enhancer of the interaction between **β-catenin**, and its cognate **E3 ligase**, $SCF^{β\text{-}TrCP}$. NRX-103094 enhances the binding of pSer33/Ser37 β-catenin peptide for β-TrCP with an EC_{50} of 62 nM and a K_d of 0.6 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NRX-103095

Cat. No.: HY-141450

NRX-103095 is an enhancer of the interaction between **β-catenin**, and its cognate **E3 ligase**, $SCF^{β\text{-}TrCP}$. NRX-103095 enhances the binding of pSer33/Ser37 β-catenin peptide for β-TrCP with an EC_{50} of 163 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NRX-252114

Cat. No.: HY-111836

NRX-252114 is a potent enhancer of the interaction between **β-catenin**, and its cognate **E3 ligase**, $SCF^{β\text{-}TrCP}$. NRX-252114 enhances the binding of pSer33/S37A β-catenin peptide for β-TrCP with an EC_{50} of 6.5 nM and a K_d of 0.4 nM. NRX-252114 induces mutant β-catenin degradation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NRX-252262

Cat. No.: HY-111760

NRX-252262 is a potent enhancer of the interaction between **β-Catenin**, and its cognate **E3 ligase**, $SCF^{β\text{-}TrCP}$, induces mutant β-catenin degradation, with an EC_{50} of 3.8 nM.



Purity: 98.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NRX-2663

Cat. No.: HY-141448

NRX-2663 is an enhancer of the interaction between **β-catenin**, and its cognate **E3 ligase**, $SCF^{β\text{-}TrCP}$. NRX-2663 enhances the binding of β-catenin peptide for β-TrCP with an EC_{50} of 22.9 μM and a K_d of 54.8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Pamidronic acid

Cat. No.: HY-B0012

Pamidronic acid is a drug used to treat a broad spectrum of bone absorption diseases.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

PNU-74654

Cat. No.: HY-101130

PNU-74654 is an inhibitor of **Wnt/β-catenin** pathway with an IC_{50} of 129.8 μM in NCI-H295 cell.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Salinomycin

(Procoxacin)

Cat. No.: HY-15597

Salinomycin (Procoxacin), a polyether potassium ionophore antibiotic, selectively inhibits the growth of **gram-positive bacteria**. Salinomycin is a potent inhibitor of **Wnt/β-catenin** signaling, blocks Wnt-induced LRP6 phosphorylation.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Salinomycin sodium salt

(Salinomycin sodium; Sodium salinomycin)

Cat. No.: HY-17439

Salinomycin sodium salt (Salinomycin sodium), an antibiotic potassium ionophore, is a potent inhibitor of **Wnt/β-catenin** signaling.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

SKL2001

Cat. No.: HY-101085

SKL2001 is an agonist of the **Wnt/β-catenin** pathway, with anti-cancer activity. SKL2001 stabilizes intracellular β-catenin via disruption of the Axin/β-catenin interaction.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Tegatrabetan

(BC2059)

Cat. No.: HY-109103

Tegatrabetan (BC2059) is a **β-Catenin** antagonist. Tegatrabetan disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1).



Purity: 99.77%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

Teplinovivint

Cat. No.: HY-137454

Teplinovivint is a potent **wnt/β-catenin** signaling pathway inhibitor. Teplinovivint has anti-inflammatory activity and has the potential for tendinopathy research.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Toxoflavin

(Xanthothricin; Toxoflavine; PKF-118-310)

Cat. No.: HY-100760

Toxoflavin (Xanthothricin) is an antagonist of **transcription factor 4 (TCF4)/β-catenin complex**, also acts as an inhibitor of **KDM4A**, with antitumor activity. Antibiotic properties.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Toxoflavin-13C4

Cat. No.: HY-100760S

Toxoflavin-13C4 is the 13C-labeled Toxoflavin. Toxoflavin (Xanthothricin) is an antagonist of **transcription factor 4 (TCF4)/β-catenin complex**, also acts as an inhibitor of **KDM4A**, with antitumor activity. Antibiotic properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Triptonide

(NSC 165677; PG 492)

Cat. No.: HY-32736

Triptonide (NSC 165677) is a natural product identified in Tripterygium wilfordii Hook F.. Triptonide is a **Wnt** signaling inhibitor with an IC_{50} of appropriately 0.3nM.



Purity: 99.73%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg

UU-T02

Cat. No.: HY-117233

UU-T02 is a novel potent, selective small-molecule inhibitor of β-Catenin/T-cell factor protein-protein interaction **(β-catenin/Tcf PPI)** with a K_i of 1.36 μM. UU-T02 inhibits canonical **Wnt** signaling and the growth of colorectal cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WAY-262611

Cat. No.: HY-11035

WAY-262611 is a wingless **β-Catenin** agonist that increases bone formation rate with an EC_{50} of 0.63 μM in TCF-Luciferase assay. WAY-262611 is also a **Dkk1** inhibitor.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

WIKI4

Cat. No.: HY-16910

WIKI4 is a potent **tankyrase** inhibitor with an IC_{50} of 26 nM for **TNKS2**. WIKI4 potently inhibits **Wnt/β-catenin** signaling and that its half-maximal response dose is 75 nM.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Withanolide B

Cat. No.: HY-129566

Withanolide B is an active component of W. somnifera Dunal. Withanolide B promotes osteogenic differentiation of hBMSCs via **ERK1/2** and **Wnt/β-catenin signaling pathways**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Wnt/β-catenin agonist 2

Cat. No.: HY-141873

Wnt/β-catenin agonist 2 is a potent **Wnt** agonist. Wnt/β-catenin agonist 2 activates Wnt/β-catenin signaling and can be used in the research of diseases related to the signal transduction. (From patent WO2007078113A1, compound 39).



Purity: 99.80%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

XAV-939

Cat. No.: HY-15147

XAV-939 is a potent **tankyrase** inhibitor that targets **Wnt/β-catenin signaling**. XAV-939 stabilizes axin by inhibiting **tankyrase 1** and **tankyrase 2** (IC_{50}s of 5 and 2 nM, respectively), thereby stimulating β-catenin degradation.



Purity: 98.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

ZW4864

Cat. No.: HY-132300

ZW4864 is an orally active and selective β catenin/B-Cell lymphoma 9 protein−protein interaction (**β catenin/BCL9 PPI**) inhibitor. ZW4864 inhibits **β catenin/BCL9 PPI** with a K_i value of 0.76 μM and an IC_{50} value of 0.87 μM.



Purity: 97.08%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ZW4864 free base

Cat. No.: HY-132300A

ZW4864 (free base) is an orally active and selective β catenin/B-Cell lymphoma 9 protein−protein interaction (**β catenin/BCL9 PPI**) inhibitor. ZW4864 (free base) inhibits **β catenin/BCL9 PPI** with a K_i value of 0.76 μM and an IC_{50} value of 0.87 μM.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

β-catenin-IN-2

Cat. No.: HY-136464

β-catenin-IN-2 is a potent **β-catenin** inhibitor, compound H1B1, extracted from patent US20150374662A1. β-catenin-IN-2 can be used for the study of colorectal cancer.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

β-catenin-IN-3

Cat. No.: HY-147007

β-catenin-IN-3 (compound C2) is a potent and selective **β-catenin** inhibitor with a K_D value of 54.96 nM. β-catenin-IN-3 acts by targeting a cryptic allosteric modulation site of β-catenin. β-catenin-IN-3 can significantly reduce viability of β-catenin-driven cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-catenin-IN-37

Cat. No.: HY-115543

β-catenin-IN-37 is a selective **β-Catenin/T-cell factor protein-protein interaction** (β-catenin/Tcf PPI) inhibitor. β-catenin-IN-37 inhibits canonical Wnt signaling and the growth of colorectal cancer cells **SW480** and **HCT116** with the IC_{50} values of 20 μM and 31 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg